Are Anticholinergic Symptoms a Risk Factor for Falls in Older General Practice Patients With Polypharmacy? Study Protocol for the Development and Validation of a Prognostic Model

Background: Cumulative anticholinergic exposure, also known as anticholinergic burden, is associated with a variety of adverse outcomes. However, studies show that anticholinergic effects tend to be underestimated by prescribers, and anticholinergics are the most frequently prescribed potentially in...

Full description

Bibliographic Details
Main Authors: Truc Sophia Dinh, Ana Isabel González-González, Andreas D. Meid, Kym I. E. Snell, Henrik Rudolf, Maria-Sophie Brueckle, Jeanet W. Blom, Ulrich Thiem, Hans-Joachim Trampisch, Petra J. M. Elders, Norbert Donner-Banzhoff, Ferdinand M. Gerlach, Sebastian Harder, Marjan van den Akker, Paul P. Glasziou, Walter E. Haefeli, Christiane Muth
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2020.577747/full
id doaj-d28433595e7e4463a60a1edcc34b7af1
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Truc Sophia Dinh
Ana Isabel González-González
Ana Isabel González-González
Andreas D. Meid
Kym I. E. Snell
Henrik Rudolf
Maria-Sophie Brueckle
Jeanet W. Blom
Ulrich Thiem
Ulrich Thiem
Hans-Joachim Trampisch
Petra J. M. Elders
Norbert Donner-Banzhoff
Ferdinand M. Gerlach
Sebastian Harder
Marjan van den Akker
Paul P. Glasziou
Walter E. Haefeli
Christiane Muth
Christiane Muth
spellingShingle Truc Sophia Dinh
Ana Isabel González-González
Ana Isabel González-González
Andreas D. Meid
Kym I. E. Snell
Henrik Rudolf
Maria-Sophie Brueckle
Jeanet W. Blom
Ulrich Thiem
Ulrich Thiem
Hans-Joachim Trampisch
Petra J. M. Elders
Norbert Donner-Banzhoff
Ferdinand M. Gerlach
Sebastian Harder
Marjan van den Akker
Paul P. Glasziou
Walter E. Haefeli
Christiane Muth
Christiane Muth
Are Anticholinergic Symptoms a Risk Factor for Falls in Older General Practice Patients With Polypharmacy? Study Protocol for the Development and Validation of a Prognostic Model
Frontiers in Pharmacology
aged [MesH]
anticholinergic burden
accidental falls [MeSH]
general practice
prediction model
prognosis research
author_facet Truc Sophia Dinh
Ana Isabel González-González
Ana Isabel González-González
Andreas D. Meid
Kym I. E. Snell
Henrik Rudolf
Maria-Sophie Brueckle
Jeanet W. Blom
Ulrich Thiem
Ulrich Thiem
Hans-Joachim Trampisch
Petra J. M. Elders
Norbert Donner-Banzhoff
Ferdinand M. Gerlach
Sebastian Harder
Marjan van den Akker
Paul P. Glasziou
Walter E. Haefeli
Christiane Muth
Christiane Muth
author_sort Truc Sophia Dinh
title Are Anticholinergic Symptoms a Risk Factor for Falls in Older General Practice Patients With Polypharmacy? Study Protocol for the Development and Validation of a Prognostic Model
title_short Are Anticholinergic Symptoms a Risk Factor for Falls in Older General Practice Patients With Polypharmacy? Study Protocol for the Development and Validation of a Prognostic Model
title_full Are Anticholinergic Symptoms a Risk Factor for Falls in Older General Practice Patients With Polypharmacy? Study Protocol for the Development and Validation of a Prognostic Model
title_fullStr Are Anticholinergic Symptoms a Risk Factor for Falls in Older General Practice Patients With Polypharmacy? Study Protocol for the Development and Validation of a Prognostic Model
title_full_unstemmed Are Anticholinergic Symptoms a Risk Factor for Falls in Older General Practice Patients With Polypharmacy? Study Protocol for the Development and Validation of a Prognostic Model
title_sort are anticholinergic symptoms a risk factor for falls in older general practice patients with polypharmacy? study protocol for the development and validation of a prognostic model
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2021-01-01
description Background: Cumulative anticholinergic exposure, also known as anticholinergic burden, is associated with a variety of adverse outcomes. However, studies show that anticholinergic effects tend to be underestimated by prescribers, and anticholinergics are the most frequently prescribed potentially inappropriate medication in older patients. The grading systems and drugs included in existing scales to quantify anticholinergic burden differ considerably and do not adequately account for patients’ susceptibility to medications. Furthermore, their ability to link anticholinergic burden with adverse outcomes such as falls is unclear. This study aims to develop a prognostic model that predicts falls in older general practice patients, to assess the performance of several anticholinergic burden scales, and to quantify the added predictive value of anticholinergic symptoms in this context.Methods: Data from two cluster-randomized controlled trials investigating medication optimization in older general practice patients in Germany will be used. One trial (RIME, n = 1,197) will be used for the model development and the other trial (PRIMUM, n = 502) will be used to externally validate the model. A priori, candidate predictors will be selected based on a literature search, predictor availability, and clinical reasoning. Candidate predictors will include socio-demographics (e.g. age, sex), morbidity (e.g. single conditions), medication (e.g. polypharmacy, anticholinergic burden as defined by scales), and well-being (e.g. quality of life, physical function). A prognostic model including sociodemographic and lifestyle-related factors, as well as variables on morbidity, medication, health status, and well-being, will be developed, whereby the prognostic value of extending the model to include additional patient-reported symptoms will be also assessed. Logistic regression will be used for the binary outcome, which will be defined as “no falls” vs. “≥1 fall” within six months of baseline, as reported in patient interviews.Discussion: As the ability of different anticholinergic burden scales to predict falls in older patients is unclear, this study may provide insights into their relative importance as well as into the overall contribution of anticholinergic symptoms and other patient characteristics. The results may support general practitioners in their clinical decision-making and in prescribing fewer medications with anticholinergic properties.
topic aged [MesH]
anticholinergic burden
accidental falls [MeSH]
general practice
prediction model
prognosis research
url https://www.frontiersin.org/articles/10.3389/fphar.2020.577747/full
work_keys_str_mv AT trucsophiadinh areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel
AT anaisabelgonzalezgonzalez areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel
AT anaisabelgonzalezgonzalez areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel
AT andreasdmeid areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel
AT kymiesnell areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel
AT henrikrudolf areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel
AT mariasophiebrueckle areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel
AT jeanetwblom areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel
AT ulrichthiem areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel
AT ulrichthiem areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel
AT hansjoachimtrampisch areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel
AT petrajmelders areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel
AT norbertdonnerbanzhoff areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel
AT ferdinandmgerlach areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel
AT sebastianharder areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel
AT marjanvandenakker areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel
AT paulpglasziou areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel
AT walterehaefeli areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel
AT christianemuth areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel
AT christianemuth areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel
_version_ 1724336881564385280
spelling doaj-d28433595e7e4463a60a1edcc34b7af12021-01-15T13:50:42ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-01-011110.3389/fphar.2020.577747577747Are Anticholinergic Symptoms a Risk Factor for Falls in Older General Practice Patients With Polypharmacy? Study Protocol for the Development and Validation of a Prognostic ModelTruc Sophia Dinh0Ana Isabel González-González1Ana Isabel González-González2Andreas D. Meid3Kym I. E. Snell4Henrik Rudolf5Maria-Sophie Brueckle6Jeanet W. Blom7Ulrich Thiem8Ulrich Thiem9Hans-Joachim Trampisch10Petra J. M. Elders11Norbert Donner-Banzhoff12Ferdinand M. Gerlach13Sebastian Harder14Marjan van den Akker15Paul P. Glasziou16Walter E. Haefeli17Christiane Muth18Christiane Muth19Institute of General Practice, Goethe-University Frankfurt, Frankfurt, GermanyInstitute of General Practice, Goethe-University Frankfurt, Frankfurt, GermanyRed de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Madrid, SpainDepartment of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Heidelberg, GermanyCentre for Prognosis Research, School of Medicine, Keele University, Staffordshire, United KingdomDepartment of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, GermanyInstitute of General Practice, Goethe-University Frankfurt, Frankfurt, GermanyDepartment of Public Health and Primary Care, Leiden University Medical Center, Leiden, NetherlandsChair of Geriatrics and Gerontology, University Clinic Eppendorf, Hamburg, GermanyDepartment of Geriatrics, Immanuel Albertinen Diakonie, Albertinen-Haus, Hamburg, GermanyDepartment of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, GermanyAmsterdam UMC, General Practice and Elderly Care Medicine, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, Netherlands0Department of General Practice/Family Medicine, Philipps University Marburg, Marburg, GermanyInstitute of General Practice, Goethe-University Frankfurt, Frankfurt, Germany1Institute of Clinical Pharmacology, Goethe-University Frankfurt am Main, Frankfurt am Main, GermanyInstitute of General Practice, Goethe-University Frankfurt, Frankfurt, Germany2Faculty of Health Sciences and Medicine, Bond University, Robina, QLD, AustraliaDepartment of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Heidelberg, GermanyInstitute of General Practice, Goethe-University Frankfurt, Frankfurt, Germany3Department of General Practice and Family Medicine, Medical Faculty OWL, University of Bielefeld, Bielefeld, GermanyBackground: Cumulative anticholinergic exposure, also known as anticholinergic burden, is associated with a variety of adverse outcomes. However, studies show that anticholinergic effects tend to be underestimated by prescribers, and anticholinergics are the most frequently prescribed potentially inappropriate medication in older patients. The grading systems and drugs included in existing scales to quantify anticholinergic burden differ considerably and do not adequately account for patients’ susceptibility to medications. Furthermore, their ability to link anticholinergic burden with adverse outcomes such as falls is unclear. This study aims to develop a prognostic model that predicts falls in older general practice patients, to assess the performance of several anticholinergic burden scales, and to quantify the added predictive value of anticholinergic symptoms in this context.Methods: Data from two cluster-randomized controlled trials investigating medication optimization in older general practice patients in Germany will be used. One trial (RIME, n = 1,197) will be used for the model development and the other trial (PRIMUM, n = 502) will be used to externally validate the model. A priori, candidate predictors will be selected based on a literature search, predictor availability, and clinical reasoning. Candidate predictors will include socio-demographics (e.g. age, sex), morbidity (e.g. single conditions), medication (e.g. polypharmacy, anticholinergic burden as defined by scales), and well-being (e.g. quality of life, physical function). A prognostic model including sociodemographic and lifestyle-related factors, as well as variables on morbidity, medication, health status, and well-being, will be developed, whereby the prognostic value of extending the model to include additional patient-reported symptoms will be also assessed. Logistic regression will be used for the binary outcome, which will be defined as “no falls” vs. “≥1 fall” within six months of baseline, as reported in patient interviews.Discussion: As the ability of different anticholinergic burden scales to predict falls in older patients is unclear, this study may provide insights into their relative importance as well as into the overall contribution of anticholinergic symptoms and other patient characteristics. The results may support general practitioners in their clinical decision-making and in prescribing fewer medications with anticholinergic properties.https://www.frontiersin.org/articles/10.3389/fphar.2020.577747/fullaged [MesH]anticholinergic burdenaccidental falls [MeSH]general practiceprediction modelprognosis research